{"nctId":"NCT00467259","briefTitle":"Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women","startDateStruct":{"date":"2007-04"},"conditions":["Hypoactive Sexual Desire Disorder"],"count":1271,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo patch"]},{"label":"Testosterone","type":"EXPERIMENTAL","interventionNames":["Drug: Testosterone Transdermal System"]}],"interventions":[{"name":"Testosterone Transdermal System","otherNames":[]},{"name":"Placebo patch","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women will be screened for study participation and must be at least one year post menopausal, 45-70 years old, in general good health, and may or may not be on hormone therapy, and must have low sexual desire which causes distress.\n\nExclusion Criteria:\n\n* Women will be screened for study participation and must not be using androgen therapy or have any medical, physical, psychological, or pharmacological condition that could make participation unsafe or confound the safety evaluation.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"45 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1","description":"Incidence measured is number of patients with endometrial hyperplasia/number of patients with evaluable biopsies","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With HSDD Using Concomitant Estrogen and Progestin, Year 1","description":"Incidence measured is number of patients with endometrial hyperplasia/number of patients with evaluable biopsies","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Endometrial Hyperplasia in Naturally Postmenopausal Women With HSDD Using Concomitant Estrogen & Progestin Combined With Those Not Using Estrogen & Progestin Therapy, Year 1","description":"Incidence measured is number of patients with endometrial hyperplasia/number of patients with evaluable biopsies","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":251},"commonTop":["Application Site Reaction","Weight Increased","Hirsutism","Upper Respiratory Tract Infection","Hypertension"]}}}